Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
431 studies found for:    "Hemophilia A"
Show Display Options
Rank Status Study
1 Active, not recruiting Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
Condition: Hemophilia A
Intervention:
2 Completed Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A
Condition: Hemophilia A
Interventions: Biological: Biostate® [SP];   Biological: Biostate® [RP]
3 Completed Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
Condition: Hemophilia A
Intervention: Drug: ReFacto
4 Completed Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
Condition: Hemophilia A
Interventions: Drug: ReFacto;   Drug: Advante
5 Completed Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
Condition: Hemophilia A
Interventions: Biological: Moroctocog alfa ( AF-CC);   Procedure: Laboratory tests
6 Recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU
7 Completed Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
Condition: Hemophilia A
Interventions: Genetic: ReFacto AF;   Genetic: B-Domain deleted Recombinant Factor VIII;   Genetic: BDDrFVIII
8 Completed
Has Results
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
9 Active, not recruiting A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BAY94-9027
10 Recruiting Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
Condition: Hemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
11 Completed Study of Biostate® in Children With Hemophilia A
Condition: Hemophilia A
Intervention: Biological: Biostate
12 Completed Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
Condition: Hemophilia A
Intervention: Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
13 Completed
Has Results
Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Condition: Hemophilia A
Intervention: Biological: ReFacto AF
14 Recruiting A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)
Condition: Hemophilia A
Intervention: Drug: Emicizumab
15 Completed Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A
Condition: Hemophilia A
Intervention: Drug: GreenGene
16 Enrolling by invitation Platelet Function in Patients With Hemophilia A
Condition: Hemophilia A
Intervention:
17 Completed Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
Condition: Hemophilia A
Intervention: Drug: Antihemophilic factor, recombinant, manufactured protein-free
18 Completed
Has Results
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Condition: Hemophilia A
Intervention: Biological: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
19 Completed Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
Condition: Severe Haemophilia A
Intervention: Drug: Pharmacokinetic based dosage change
20 Completed Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.